Renovion Raises $8.1M to Advance Lung Inflammation, Mucus Treatment

Renovion Raises $8.1M to Advance Lung Inflammation, Mucus Treatment

Renovion has raised $8.1 million in a financing round, supporting further development and planned clinical testing of ARINA-1, a nebulized treatment for chronic lung diseases like cystic fibrosis (CF) and non-CF bronchiectasis, and for lung transplants.

“Patient and laboratory studies have shown that ARINA-1 significantly improves mucus clearance while reducing inflammation. There are limited options available and we see a great opportunity to help these patients,” Dan Copeland, CEO at Renovion, said in a press release. “This funding will be instrumental in progressing our clinical [lung disease] programs.” 

ARINA-1 works to restore the lungs’ innate immune system, the first line of defense against microbes and foreign particles, to improve mucus clearance and lower inflammation. The innate immune system is activated when it comes into contact with foreign bodies.

“My lab has worked extensively with ARINA-1 to determine how the drug effects CF mucus and mucus transport. CF mucus is severely problematic, and ARINA-1 strongly augments mucus transport in CF cells that are defective for this trait,”said Steven Rowe, MD, director of the Cystic Fibrosis Research Center at the University of Alabama Birmingham.

The candidate treatment is inhaled using an investigational eFlow nebulizer by Pari Group, being developed to deliver an optimal therapy dose to the airways. Patient data shows a good safety profile and significant mucus clearance with ARINA-1 therapy, Renovion reported on its website.A Phase 2/3 pivotal clinical trial assessing ARINA-1 in people who have had a lung transplant is planned for early 2021, followed by clinical trials in CF and non-CF bronchiectasis patients.“Based on our studies demonstrating that ARINA-1 is substantially more effective than hypertonic saline for mucus clearanc [mucus thinners] in CF cells, the potential for ARINA-1 to help people with CF improve clinically is promising,” Rowe said.

“Importantly, CF mucus is emblematic of difficult to treat mucus in other airway diseases. As ARINA-1’s mechanism is multi-faceted, it also has the potential to help in other diseases,” he added.

ARINA-1 has been designated an orphan drug as a potential treatment of lung transplant complications and CF by the U.S. Food and Drug Administration. 

The Series A financing round was led by White Rock Capital Management.

Total Posts: 336

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Latest Posts
  • Respiratory Care
  • ELX-02 trials enrollment
  • mucus and bacteria
  • Staphylococcus aureus

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?